This study uses the National Inpatient Sample (2002-2014) to project the future volume of revision hip and knee arthroplasty in the United States to 2030. Poisson and linear regression models estimate growth by age group and by mode of failure. The goal is to anticipate revision burden so institutions can plan revision-specific care pathways.
When you evaluate a painful arthroplasty, the differential is shaped by the dominant failure modes this paper quantifies. For a painful knee replacement, think infection and aseptic loosening first. For a painful hip, periprosthetic fracture and infection lead the rising indications.
The most clinically important signal is the surge in revisions among patients aged 55-64. Younger, higher-demand patients are outliving their implants and face worse revision survivorship and dismal return-to-work rates.
This directly supports the board concept that revision arthroplasty differs fundamentally from primary surgery: more infection, more blood loss, longer stays, higher cost, and nonhome discharge.
The authors argue institutions should build revision-specific perioperative protocols rather than apply primary pathways. For a resident, the takeaway is to workup a failed implant systematically (history, exam, inflammatory markers, aspiration, imaging) and counsel younger patients honestly that a revision is more likely in their lifetime.
This study uses the National Inpatient Sample (2002-2014) to project the future volume of revision hip and knee arthroplasty in the United States to 2030. Poisson and linear regression models estimate growth by age group and by mode of failure. The goal is to anticipate revision burden so institutions can plan revision-specific care pathways.
When you evaluate a painful arthroplasty, the differential is shaped by the dominant failure modes this paper quantifies. For a painful knee replacement, think infection and aseptic loosening first. For a painful hip, periprosthetic fracture and infection lead the rising indications.
The most clinically important signal is the surge in revisions among patients aged 55-64. Younger, higher-demand patients are outliving their implants and face worse revision survivorship and dismal return-to-work rates.
This directly supports the board concept that revision arthroplasty differs fundamentally from primary surgery: more infection, more blood loss, longer stays, higher cost, and nonhome discharge.
The authors argue institutions should build revision-specific perioperative protocols rather than apply primary pathways. For a resident, the takeaway is to workup a failed implant systematically (history, exam, inflammatory markers, aspiration, imaging) and counsel younger patients honestly that a revision is more likely in their lifetime.